We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+45.46%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.56B
AUM Growth
+$624M
Cap. Flow
+$9.78M
Cap. Flow %
0.38%
Top 10 Hldgs %
47.45%
Holding
133
New
23
Increased
24
Reduced
15
Closed
18

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$32.4M
2
GPCR icon
Structure Therapeutics
GPCR
+$20.5M
3
RELY icon
Remitly
RELY
+$19.8M
4
TNGX icon
Tango Therapeutics
TNGX
+$17M
5
RCUS icon
Arcus Biosciences
RCUS
+$13.5M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$44.9M
2
APGE icon
Apogee Therapeutics
APGE
+$25.8M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$24M
4
AKRO
Akero Therapeutics
AKRO
+$17M
5
IRON icon
Disc Medicine
IRON
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.03%
2 Technology 5.1%
3 Communication Services 1.94%
4 Consumer Discretionary 0.86%
5 Real Estate 0.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.44B
$344M 13.48%
9,250,005
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.94B
$194M 7.59%
3,428,150
– –
ONC
3
BeOne Medicines Ltd
ONC
$39.4B
$168M 6.57%
492,990
-17,000
-3% -$5.16M
ARWR icon
4
Arrowhead Research
ARWR
$12.4B
$92.1M 3.6%
2,669,880
– –
BCAX
5
Bicara Therapeutics
BCAX
$1.84B
$82.4M 3.22%
5,216,969
– –
CNTA
6
DELISTED
Centessa Pharmaceuticals
CNTA
$78.3M 3.06%
3,227,517
-232,512
-7% -$4.13M
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.92B
$70.3M 2.75%
1,688,611
– –
EWTX icon
8
Edgewise Therapeutics
EWTX
$4.73B
$63.2M 2.47%
3,897,099
+736,801
+23% +$10.5M
IRON icon
9
Disc Medicine
IRON
$2.97B
$60.4M 2.36%
913,401
-186,000
-17% -$11.1M
DYN icon
10
Dyne Therapeutics
DYN
$4.9B
$59.8M 2.34%
4,729,174
-107,263
-2% -$1.22M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$58.3M 2.28%
2,578,396
– –
RNAM
12
DELISTED
Avidity Biosciences
RNAM
$56M 2.19%
1,285,610
+175,000
+16% +$7.07M
STOK icon
13
Stoke Therapeutics
STOK
$2.11B
$52.8M 2.07%
2,247,347
– –
LXRX icon
14
Lexicon Pharmaceuticals
LXRX
$1.1B
$52.5M 2.06%
38,918,903
– –
RYTM icon
15
Rhythm Pharmaceuticals
RYTM
$7.96B
$50.5M 1.98%
499,975
+90,233
+22% +$8.38M
TNGX icon
16
Tango Therapeutics
TNGX
$4.41B
$49.4M 1.93%
5,883,188
+2,518,374
+75% +$17M
RVMD icon
17
Revolution Medicines
RVMD
$44B
$48.7M 1.91%
1,043,720
+104,965
+11% +$4.11M
ASND icon
18
Ascendis Pharma A/S
ASND
$16.8B
$46.9M 1.83%
235,862
-10,081
-4% -$1.88M
RZLT icon
19
Rezolute
RZLT
$452M
$45.8M 1.79%
+4,870,000
New +$32.4M
SLDB icon
20
Solid Biosciences
SLDB
$900M
$45.8M 1.79%
7,415,905
– –
SEPN
21
Septerna Inc
SEPN
$1.75B
$41.4M 1.62%
2,202,514
– –
RCUS icon
22
Arcus Biosciences
RCUS
$3.64B
$39.6M 1.55%
2,912,077
+1,300,000
+81% +$13.5M
TSHA icon
23
Taysha Gene Therapies
TSHA
$1.89B
$36M 1.41%
11,014,737
– –
TBLA icon
24
Taboola.com
TBLA
$1.11B
$34M 1.33%
9,969,495
– –
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.12B
$32.6M 1.28%
812,761
– –
1
2 3 4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q3 2025 Portfolio in Review

As of Q3 2025, Siren LLC held 133 positions worth $2.56B, up 32% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Siren LLC's Q3 2025 filing shows 23 new, 24 increased, 15 reduced and 18 closed positions. Its largest new stake was Rezolute: 4,870,000 shares worth $45.8M. The largest sale was Merus, an estimated $44.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 90% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q3 2025 buy was Rezolute: 4,870,000 shares worth $45.8M.
  • Siren LLC added most to Remitly in Q3 2025, an estimated $19.8M increase.
  • Siren LLC's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $11.1M.
  • Siren LLC fully exited Merus in Q3 2025, selling an estimated $44.9M.
  • Siren LLC's ten largest holdings make up 47% of its $2.56B portfolio in Q3 2025.
  • Siren LLC opened 23 new positions and closed 18 in Q3 2025.
  • Siren LLC's portfolio value rose 32% quarter-over-quarter to $2.56B.

Based on Siren LLC's 13F filing for Q3 2025, filed 13 Nov 2025.